A Randomized, Double-Blind, Placebo-controlled Phase III Study of DE-766 with Cisplatin/Vinorellbine plus Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Squamous Cell Lung Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-controlled Phase III Study of DE-766 with Cisplatin/Vinorellbine plus Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Squamous Cell Lung Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 29 Apr 2014 Planned End Date changed to 30 Jun 2021, according to JapicCTI.
    • 25 Apr 2014 Status changed from recruiting to discontinued, according to a Daiichi Sankyo media release.
    • 02 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top